The immunohistochemical (IHC) 4 + Clinical (C) score is a prognostic tool based on quantitative assessment of immunohistochemical biomarkers (ER, Progesterone receptor (PgR), HER2 and Ki67) and the clinicopathologic variables (tumour grade, size, nodal status, tumour grade, treatment with AI or tamoxifen) [10–12]. Here, ERBB2 is linked to neoplasm.